146 related articles for article (PubMed ID: 15544619)
21. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury.
Mead RJ; Singhrao SK; Neal JW; Lassmann H; Morgan BP
J Immunol; 2002 Jan; 168(1):458-65. PubMed ID: 11751993
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats.
Iyer A; Woodruff TM; Wu MC; Stylianou C; Reid RC; Fairlie DP; Taylor SM; Brown L
J Cardiovasc Pharmacol; 2011 Nov; 58(5):479-86. PubMed ID: 21753735
[TBL] [Abstract][Full Text] [Related]
23. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury.
Heller T; Hennecke M; Baumann U; Gessner JE; zu Vilsendorf AM; Baensch M; Boulay F; Kola A; Klos A; Bautsch W; Köhl J
J Immunol; 1999 Jul; 163(2):985-94. PubMed ID: 10395696
[TBL] [Abstract][Full Text] [Related]
24. Identification of a new class of small molecule C5a receptor antagonists.
Chen JJ; Cole DC; Ciszewski G; Crouse K; Ellingboe JW; Nowak P; Tawa GJ; Berstein G; Li W
Bioorg Med Chem Lett; 2010 Jan; 20(2):662-4. PubMed ID: 20004096
[TBL] [Abstract][Full Text] [Related]
25. Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis.
Riedemann NC; Guo RF; Hollmann TJ; Gao H; Neff TA; Reuben JS; Speyer CL; Sarma JV; Wetsel RA; Zetoune FS; Ward PA
FASEB J; 2004 Feb; 18(2):370-2. PubMed ID: 14688199
[TBL] [Abstract][Full Text] [Related]
26. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation.
Vergunst CE; Gerlag DM; Dinant H; Schulz L; Vinkenoog M; Smeets TJ; Sanders ME; Reedquist KA; Tak PP
Rheumatology (Oxford); 2007 Dec; 46(12):1773-8. PubMed ID: 17965442
[TBL] [Abstract][Full Text] [Related]
27. Expression of C5a in the brain does not exacerbate experimental autoimmune encephalomyelitis.
Reiman R; Campos Torres A; Martin BK; Ting JP; Campbell IL; Barnum SR
Neurosci Lett; 2005 Dec; 390(3):134-8. PubMed ID: 16154690
[TBL] [Abstract][Full Text] [Related]
28. Complement C5a receptor antagonist attenuates multiple organ injury in a model of ruptured abdominal aortic aneurysm.
Harkin DW; Romaschin A; Taylor SM; Rubin BB; Lindsay TF
J Vasc Surg; 2004 Jan; 39(1):196-206. PubMed ID: 14718840
[TBL] [Abstract][Full Text] [Related]
29. Acute inflammation in peritoneal dialysis: experimental studies in rats. Characterization of regulatory mechanisms.
Bazargani F
Swed Dent J Suppl; 2005; (171):1-57, i. PubMed ID: 15847249
[TBL] [Abstract][Full Text] [Related]
30. C5a receptor antagonists for the treatment of inflammation.
Sumichika H
Curr Opin Investig Drugs; 2004 May; 5(5):505-10. PubMed ID: 15202723
[TBL] [Abstract][Full Text] [Related]
31. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat.
Woodruff TM; Strachan AJ; Dryburgh N; Shiels IA; Reid RC; Fairlie DP; Taylor SM
Arthritis Rheum; 2002 Sep; 46(9):2476-85. PubMed ID: 12355496
[TBL] [Abstract][Full Text] [Related]
32. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors.
Oppermann M; Götze O
Immunology; 1994 Aug; 82(4):516-21. PubMed ID: 7835913
[TBL] [Abstract][Full Text] [Related]
33. Neutrophil C5a receptor and the outcome in a rat model of sepsis.
Guo RF; Riedemann NC; Bernacki KD; Sarma VJ; Laudes IJ; Reuben JS; Younkin EM; Neff TA; Paulauskis JD; Zetoune FS; Ward PA
FASEB J; 2003 Oct; 17(13):1889-91. PubMed ID: 12897064
[TBL] [Abstract][Full Text] [Related]
34. C5a receptor targeting in neointima formation after arterial injury in atherosclerosis-prone mice.
Shagdarsuren E; Bidzhekov K; Mause SF; Simsekyilmaz S; Polakowski T; Hawlisch H; Gessner JE; Zernecke A; Weber C
Circulation; 2010 Sep; 122(10):1026-36. PubMed ID: 20733098
[TBL] [Abstract][Full Text] [Related]
35. Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection.
Rus H; Cudrici C; Niculescu F; Shin ML
J Neuroimmunol; 2006 Nov; 180(1-2):9-16. PubMed ID: 16905199
[TBL] [Abstract][Full Text] [Related]
36. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.
Corrales L; Ajona D; Rafail S; Lasarte JJ; Riezu-Boj JI; Lambris JD; Rouzaut A; Pajares MJ; Montuenga LM; Pio R
J Immunol; 2012 Nov; 189(9):4674-83. PubMed ID: 23028051
[TBL] [Abstract][Full Text] [Related]
37. Never make assumptions: the complicated role of complement in urinary tract infections.
Thurman JM; Nemenoff RA
Kidney Int; 2016 Sep; 90(3):469-71. PubMed ID: 27521106
[TBL] [Abstract][Full Text] [Related]
38. The role of the complement system and the activation fragment C5a in the central nervous system.
Woodruff TM; Ager RR; Tenner AJ; Noakes PG; Taylor SM
Neuromolecular Med; 2010 Jun; 12(2):179-92. PubMed ID: 19763906
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration.
Woodruff TM; Crane JW; Proctor LM; Buller KM; Shek AB; de Vos K; Pollitt S; Williams HM; Shiels IA; Monk PN; Taylor SM
FASEB J; 2006 Jul; 20(9):1407-17. PubMed ID: 16816116
[TBL] [Abstract][Full Text] [Related]
40. Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727.
Robertson N; Rappas M; Doré AS; Brown J; Bottegoni G; Koglin M; Cansfield J; Jazayeri A; Cooke RM; Marshall FH
Nature; 2018 Jan; 553(7686):111-114. PubMed ID: 29300009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
